- Home
- ACRS vs MAPS Comparison
ACRS vs MAPS Comparison
Compare ACRS & MAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- MAPS
- Stock Information
- Founded
- ACRS 2012
- MAPS 2008
- Country
- ACRS United States
- MAPS United States
- Employees
- ACRS N/A
- MAPS N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- MAPS Computer Software: Prepackaged Software
- Sector
- ACRS Health Care
- MAPS Technology
- Exchange
- ACRS Nasdaq
- MAPS Nasdaq
- Market Cap
- ACRS 137.5M
- MAPS 131.9M
- IPO Year
- ACRS 2015
- MAPS N/A
- Fundamental
- Price
- ACRS $1.46
- MAPS $1.04
- Analyst Decision
- ACRS Strong Buy
- MAPS Strong Buy
- Analyst Count
- ACRS 8
- MAPS 1
- Target Price
- ACRS $9.71
- MAPS $2.61
- AVG Volume (30 Days)
- ACRS 709.4K
- MAPS 632.3K
- Earning Date
- ACRS 05-08-2025
- MAPS 05-08-2025
- Dividend Yield
- ACRS N/A
- MAPS N/A
- EPS Growth
- ACRS N/A
- MAPS N/A
- EPS
- ACRS N/A
- MAPS 0.08
- Revenue
- ACRS $17,777,000.00
- MAPS $184,737,000.00
- Revenue This Year
- ACRS N/A
- MAPS $0.86
- Revenue Next Year
- ACRS $14.59
- MAPS $12.85
- P/E Ratio
- ACRS N/A
- MAPS $12.74
- Revenue Growth
- ACRS N/A
- MAPS N/A
- 52 Week Low
- ACRS $0.99
- MAPS $0.70
- 52 Week High
- ACRS $5.17
- MAPS $1.65
- Technical
- Relative Strength Index (RSI)
- ACRS 61.33
- MAPS 42.23
- Support Level
- ACRS $1.22
- MAPS $1.01
- Resistance Level
- ACRS $1.56
- MAPS $1.09
- Average True Range (ATR)
- ACRS 0.09
- MAPS 0.06
- MACD
- ACRS 0.03
- MAPS -0.01
- Stochastic Oscillator
- ACRS 75.00
- MAPS 15.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About MAPS WM Technology Inc.
WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on our marketplace ads.